Showing 1,341 - 1,360 results of 102,467 for search '(( 12 mg decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.67s Refine Results
  1. 1341
  2. 1342
  3. 1343
  4. 1344

    Diagnostic performance of blood parameters to discriminate abnormal from normal MAD activity (A) and decreased from absent MAD activity (B). by Fabrice Rannou (775170)

    Published 2015
    “…(B) Classifiers for the differentiation of Absent (n = 5) from Decreased (n = 6) MAD activity. 50% PMP: 50% from predicted maximal power (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132972#sec006" target="_blank">Methods</a>), R: Recovery from exercise, Se: Sensibility, Sp: Specificity, Acc: Accuracy, PPV: Positive predictive value, NPV: Negative predictive value, LR+: Positive likelihood ratio, LR-: Negative likelihood ratio, DOR: Diagnostic odds ratio, NC: Not calculable.…”
  5. 1345
  6. 1346

    A Point Mutation in a lincRNA Upstream of <i>GDNF</i> Is Associated to a Canine Insensitivity to Pain: A Spontaneous Model for Human Sensory Neuropathies by Jocelyn Plassais (564630)

    Published 2016
    “…This variant, located 90 kb upstream of the <i>GDNF</i> gene, a highly relevant neurotrophic factor candidate gene, lies in a long intergenic non-coding RNAs (lincRNA), <i>GDNF-AS</i>. …”
  7. 1347
  8. 1348
  9. 1349
  10. 1350

    S5 Fig - by Cynthia Alsayyah (18452506)

    Published 2024
    “…This indicates that inhibiting the entry of citrate into mitochondria induces the same effects as inhibiting the synthesis of peroxisomal citrate (see <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3002602#pbio.3002602.g005" target="_blank">Fig 5E</a>). …”
  11. 1351
  12. 1352

    Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy by Yong-Chul Kim (1637572)

    Published 2013
    “…In the Tac group, the pcUACRs were –60.2±28.2%, –62.2±33.9%, –48.5±29.8%, and –55.5±24.0%, and, in the control group, –6.8±32.2%, –2.5±35.9%, –12.7±34.2%, and –21.9±30.6%, at 4-week, 8-week, 12-week, and 16-week visits, respectively. …”
  13. 1353
  14. 1354
  15. 1355
  16. 1356
  17. 1357
  18. 1358
  19. 1359
  20. 1360